Reliable manufacturing you can count on for your patients
A pegfilgrastim biosimilar proudly manufactured in the USA.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) suggest pegfilgrastim use to support clinical outcomes during chemotherapy.†4See the guidelines
Returning to the clinic to receive UDENYCA® may increase patient comfort.See patient survey results
Receive occasional emails to learn more about UDENYCA®, reimbursement, and support services for your chemotherapy patients.Sign up now
*January 2019 through December 2020.
†Other suggestions for therapy are included in the NCCN Guidelines®.
References: 1. U.S. Food and Drug Administration. Regulatory Education for Industry, Facilities and Equipment: cGMP Requirements Presentation. 2015. 2. U.S. Food and Drug Administration. Drug Establishments Current Registration Site, Drug Databases. Accessed October 4, 2022. https://www.accessdata.fda.gov/scripts/cder/drls/getdrls.cfm 3. Data on file. Coherus BioSciences, Inc.; 2021. 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hematopoietic Growth Factors V.1.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed September 30, 2022. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.